Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

BACKGROUND: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. RESULTS: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 − 0.63; p < 0.00001) and 0.87 (95% CI, 0....

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Claudia, De Felice, Francesca, Palaia, Innocenza, Musella, Angela, Di Donato, Violante, Gasparri, Maria Luisa, Musio, Daniela, Muzii, Ludovico, Tombolini, Vincenzo, Panici, Pierluigi Benedetti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914353/
https://www.ncbi.nlm.nih.gov/pubmed/26657509
http://dx.doi.org/10.18632/oncotarget.6507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914353/
https://www.ncbi.nlm.nih.gov/pubmed/26657509
http://dx.doi.org/10.18632/oncotarget.6507

Ejemplares similares